Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?

ABSTRACT: It is striking that all marketed SARS-CoV-2 vaccines are developed for intramuscular administration designed to produce humoral and cell mediated immune responses, preventing viremia and the COVID-19 syndrome. They have a high degree of efficacy in humans (70-95%) depending on the type of vaccine. However, little protection is provided against viral replication and shedding in the upper airways due to the lack of a local sIgA immune response, indicating a risk of transmission of virus from vaccinated individuals. A range of novel nasal COVID-19 vaccines are in development and preclinical results in non-human primates have shown a promising prevention of replication and shedding of virus due to the induction of mucosal immune response (sIgA) in upper and lower respiratory tracts as well as

SUBMITTER: Tiboni M 

PROVIDER: S-EPMC8099545 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature